Company Profile

Involved in SBIR in its early years, in June 2020 it was announced that the British firm Croda International had successfully completed the deal to buy Avanti Polar Lipids, Inc., which provides delivery systems for complex drugs - manufacturing and supplying lipids to researchers and pharmaceutical companies in the United States and internationally. The combination of two life science leaders brings together Avanti’s expertise in lipid-based drug delivery solutions through its research products and pharmaceutical services and Croda’s range of life science products and cGMP manufacturing capabilities to expand their respective breadth of products and services for biotechnology businesses, academic institutions and pharmaceutical companies globally. Founded in 1967 the firm has been a leader in the development and manufacturing of high-purity lipids that are increasingly utilized as drug delivery solutions for complex therapeutic drugs and next generation mRNA vaccines. The Company operates from its campus in Alabama with its skilled workforce of approximately 150 employees, including over 100 scientists. Throughout Avanti’s history it has been an innovator in lipid based products and applications for the life sciences markets and currently serves thousands of leading biopharmaceutical companies and researchers around the world. A leader in developing lipids for life science research and currently offers over 2,000 lipid and adjuvant products serving over 3000 customers globally, the Company has also offered pharmaceutical services leveraging its lipid based expertise to develop and supply drug delivery solutions for complex therapeutics. Avanti provides a comprehensive range of services from formulation and analytical services through cGMP manufacturing of synthetic lipids and adjuvants for clinical and commercial applications. Avanti’s know-how and technologies are highly complementary to Croda’s capabilities in drug delivery systems, vaccine adjuvants and immunotherapy. Avanti will be able to combine its leading position in pharmaceutical lipid-based applications with Croda’s access to global markets, greater manufacturing capacity and a broader set of capabilities to expand the range of products and services for the combined customer base. Avanti will continue to operate under the Avanti brand and be led by the current management team. It will be part of Croda’s Life Sciences sector and sit within its Health C